REGISTER
Gan & Lee Diabetes Product Launched in Europe
Gan & Lee Pharmaceutical has received European Commission authorization for insulin glargine injection under the brand name Ondibta across the European Union, Iceland, Liechtenstein and Norway. The long-acting basal insulin is approved for diabetes in adults, adolescents and children aged 2 years and older.

On January 14, Gan & Lee Pharmaceutical announced that it had recently received notice from the European Commission that its insulin glargine injection, branded Ondibta, had obtained marketing authorization in the European Union, Iceland, Liechtenstein, and Norway for the treatment of diabetes in adults, adolescents, and children aged 2 years and older.

Insulin glargine is a long-acting basal insulin administered subcutaneously once daily. Its glucose-lowering effect lasts 24 hours and it is characterized by a long duration of action, stable plasma concentrations without a pronounced peak, and steady glycemic control.

As of the date of the announcement, the main supplier of insulin glargine injection in Europe was Sanofi. As the originator manufacturer, Sanofi reported global sales of 2.855 billion euros for its insulin glargine product in 2024, including 819 million euros in Europe.

As of September 30, 2025, Gan & Lee Pharmaceutical had cumulatively invested RMB 936 million in research and development for the insulin glargine project.

0
0
Loading